Azacitidine Mylan is used for the treatment of adults with the following diseases, if they cannot have haematopoietic stem cell transplantation (when the patient’s bone marrow is replaced to form new bone marrow that produces healthy cells):
- myelodysplastic syndromes, a group of conditions where the bone marrow produces abnormal blood cells and not enough healthy ones. In some cases, myelodysplastic syndromes can lead to acute myeloid leukaemia (AML, a cancer affecting white blood cells called myeloid cells). Azacitidine Mylan is used in patients with an intermediate to high risk of progressing to AML or death;
- chronic myelomonocytic leukaemia (a cancer affecting white blood cells called monocytes). Azacitidine Mylan is used when the bone marrow consists of 10 to 29% abnormal cells and the bone marrow is not producing large numbers of white blood cells;
- AML that has developed from a myelodysplastic syndrome, where the bone marrow consists of 20 to 30% abnormal cells;
- AML, where the bone marrow has more than 30% abnormal cells.
Azacitidine Mylan contains the active substance azacitidine.
Azacitidine Mylan is a ‘generic medicine’. This means that Azacitidine Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Vidaza. For more information on generic medicines, see the question-and-answer document here.
Azacitidine Mylan : EPAR - Medicine overview (PDF/171.01 KB)
First published: 06/04/2020
Azacitidine Mylan : EPAR - Risk-management-plan summary (PDF/82.46 KB)
First published: 06/04/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
Mylan Ireland Limited
|Date of issue of marketing authorisation valid throughout the European Union||
24/06/2022 Azacitidine Mylan - EMEA/H/C/004984 - IB/0010
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:
- intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,
- acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,
- AML with > 30% marrow blasts according to the WHO classification.